Physician profile
Dawn H Roque
NPI 1003401480
$3,437.17
in general payments reported to CMS, 2019-2025
47 companies · $695 in 2025
The $695 reported for 2025 was more than what 81% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $227 · 2022: $579 · 2023: $833 · 2024: $1,103 · 2025: $695.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,436 · Education: $195.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,435.95 |
| Education | $195.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $386.30 | 2021-2024 | Jakafi, Monjuvi |
| Astrazeneca Pharmaceuticals LP | $228.45 | 2021-2025 | Imfinzi, Enhertu |
| Celgene Corporation | $192.70 | 2023-2025 | Pomalyst, Opdivo, Reblozyl |
| Janssen Biotech, INC. | $176.50 | 2021-2025 | Rybrevant, Imbruvica, Darzalex |
| Pfizer INC. | $153.79 | 2023-2025 | |
| Pharmacyclics LLC, An Abbvie Company | $133.34 | 2022-2023 | Imbruvica, Epkinly |
| Seagen INC. | $130.62 | 2023-2025 | Adcetris |
| Takeda Pharmaceuticals U.S.A., INC. | $121.55 | 2022-2024 | Ninlaro, Fruzaqla, Alunbrig |
| Abbvie INC. | $101.28 | 2022-2025 | |
| Rigel Pharmaceuticals, INC. | $94.51 | 2022-2024 | Tavalisse, Rezlidhia |
| Genzyme Corporation | $93.50 | 2023-2025 | |
| Merck Sharp & Dohme LLC | $93.25 | 2023-2025 | Keytruda, Welireg, Reblozyl |
| Novartis Pharmaceuticals Corporation | $92.58 | 2022-2024 | |
| Gilead Sciences, INC. | $92.49 | 2025 | Livdelzi |
| Jazz Pharmaceuticals INC. | $84.05 | 2021-2025 |
Show all 47 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $84.05 | 2023-2024 | Libtayo |
| Lilly USA, LLC | $76.74 | 2021-2025 | Verzenio, Jaypirca, Retevmo |
| Karyopharm Therapeutics INC. | $69.70 | 2023-2025 | Xpovio |
| Glaxosmithkline, LLC. | $66.50 | 2023-2025 | Ojjaara |
| Genentech USA, INC. | $64.28 | 2024-2025 | Tecentriq, Rozlytrek, Itovebi |
| Emd Serono, INC. | $61.76 | 2022-2024 | |
| E.R. Squibb & Sons, L.L.C. | $61.62 | 2022-2024 | Opdualag |
| Daiichi Sankyo INC. | $56.97 | 2023-2024 | Enhertu |
| Puma Biotechnology, INC. | $56.55 | 2022-2024 | |
| Eisai INC. | $55.81 | 2023-2024 | |
| Kyowa Kirin, INC. | $46.10 | 2022 | |
| Myovant Sciences INC. | $43.48 | 2022 | |
| Exelixis INC. | $42.46 | 2021-2025 | Cabometyx |
| Morphosys, US INC. | $40.11 | 2022-2023 | Monjuvi |
| Ipsen Biopharmaceuticals, INC | $37.42 | 2024 | Tazverik, Somatuline Depot, Onivyde |
| Tersera Therapeutics LLC | $36.43 | 2023-2025 | Xermelo, Zoladex |
| Bayer Healthcare Pharmaceuticals INC. | $33.73 | 2025 | |
| Pharmacosmos Therapeutics INC. | $33.34 | 2024 | Monoferric |
| Pharmaessentia USA Corporation | $32.35 | 2024 | Besremi |
| Beone Medicines USA, INC. | $25.89 | 2025 | Tevimbra |
| Blueprint Medicines Corporation | $25.87 | 2024 | Ayvakit |
| Deciphera Pharmaceuticals INC. | $24.05 | 2024 | Qinlock |
| Masimo Corporation | $23.12 | 2022 | |
| Sobi, INC | $22.52 | 2024 | |
| Beigene USA, INC. | $22.06 | 2024 | Brukinsa |
| Amgen INC. | $20.35 | 2022 | |
| Array Biopharma INC | $19.32 | 2021 | |
| Azurity Pharmaceuticals, INC. | $19.11 | 2024 | Vivimusta |
| Shield Therapeutics INC | $18.36 | 2023 | Accrufer |
| Genmab U.S., INC. | $16.44 | 2025 | Epkinly |
| Spectrum Pharmaceuticals INC. | $14.62 | 2025 | Rolvedon |
| Pharmaand Gmbh | $11.15 | 2025 | Rubraca |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dawn Roque listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.